Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy?
Johnson & Johnson Is on Track for $101 Billion in 2026 Sales. Is This Dividend King Still a Buy?
J&J is a healthcare giant performing very well right now, but it won't be a great fit for every investor.
By Reuben Gregg Brewer -- Nov 22, 2026 at 8:38AM EST
Key Points
- Johnson & Johnson is a leader in the pharmaceutical and medical device sectors.
- JNJ is a Dividend King with an above-market yield.
- The healthcare giant's valuation could turn some investors away from the stock.
Johnson & Johnson (JNJ +1.25%) is the kind of investment that you buy and hold for the long term. However, that doesn't mean it will be a great option for every investor. While it could be a buy for a conservative dividend investor today, many others will likely be better off putting the stock on their wish list. Here's why.
Johnson & Johnson runs a great business
It is important to understand that Johnson & Johnson has an incredible business history. Founded more than 100 years ago, the business has proven resilient, changing over time to serve its customers and reward its shareholders. Today, the company is an industry leader in both the pharmaceutical and medical devices segments of the broader healthcare sector.
Image source: Getty Images.
There are many ways that J&J's success could be highlighted, but one of the best is probably its dividend track record. The healthcare giant has increased its dividend for 64 consecutive years. That not only makes J&J a Dividend King but also gives it the longest streak of any healthcare company. A company can't build a dividend track record like that by accident; it requires a strong business model that gets executed well in good times and bad.
During the third quarter, J&J again showed how well it is run, increasing its full-year guidance for revenues and earnings. On the top line, the healthcare behemoth now projects $101.2 billion in revenue, with the bottom line at $11.10 per share. Those are both modest improvements over the previous guidance, but the direction is what's important. If you own this stock, you should be pleased with the third-quarter 2026 update.
-- Price
Who should own Johnson & Johnson?
The problem is that Wall Street knows that J&J is a well-run company. That's why the yield is 1.9%, above the market's tiny 1% and the average healthcare stock's 1.3%, but still unlikely to be enticing to investors looking to maximize the income their portfolios generate. The yield is also near its lowest levels in the past decade. That speaks to another problem: valuation.
Johnson & Johnson's price-to-sales ratio is 6.8x compared to a five-year average of 4.8x. Its price-to-earnings ratio is 42x, compared with a long-term average of 24x. And its price-to-book ratio is 8.2x versus a five-year average of 5.8x. While the P/E ratio has been biased higher by one-time charges, the overall statement here is that J&J is expensive. So value investors will probably want to stay on the sidelines.
There is, however, a place for Johnson & Johnson if you are a conservative, income-oriented investor who places a high value on dividend consistency. This is, basically, a situation where investors are paying up for quality. That said, if you are patient, you could probably buy the stock with a more attractive yield and valuation during a broad market downturn. So even here, it could be a wish-list stock. But if you are looking to buy a diversified healthcare stock that you can count on for the long term, it deserves strong consideration despite the premium price tag.
No investment is perfect, not even J&J
It would be wonderful if great companies were also cheap and had above-average dividend yields. That's just not how Wall Street works most of the time. If you have a value focus or favor high-yield stocks, J&J probably won't fit your portfolio right now. Keep it on your wish list, just in case a market downdraft opens up a buying opportunity. However, if what you are looking for is a reliable dividend stock with an above-market yield, paying a premium for J&J could still be worth it if you have a long enough time horizon.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

The Industry Is Not Bad, But the $350 Billion Lost by ETH and SOL Is the Root Cause of Industry Pessimism

Prediction: These Will Be AMD’s and Nvidia’s Stock Prices by 2028

IOSCO Warns of 'Quantum Delay' and Assesses Readiness for Quantum Threat

J.P. Morgan Says Tesla's Robotaxi Fleet Could Match Waymo's Miles by Late 2027 With 18,000 Cars. The Number That Matters Is How Much Each Car Earns.

What's Going on with The Trade Desk Stock? 3 Reasons Investors Are Losing Confidence.

Bitcoin: Network Power Rises, Profits Disappear

Altria Yields 5.8% and Has Raised Its Dividend 61 Times in 57 Years. Here's Exactly How Much $5,000 Invested Pays Each Year.

Not Lucid. Not Ford. The EV Stock Most Likely to Catch Every Refunded Cybertruck Buyer.

The Stock Market Is Doing Something for Only the 5th Time This Century, and History Says It's Obvious What Comes Next for Stocks

Morgan Stanley's Bitcoin Spot ETF MSBT Increases Holdings by 799.212 BTC Against the Trend, Total Holdings Rise to 12,448 BTC

Peter Schiff says Solana can replace Bitcoin exposure. Can it?

AMD Stock Just Plunged on a Short-Seller Report. Is This a Golden Buying Opportunity?

Tesla Just Started Selling Cybercabs, Here's What It Means for a SpaceX and Tesla Merger .

How to Protect Your Wealth Amid Geopolitical Turmoil?

Where Will Nvidia Stock Be in 20 Years? The Answer Might Surprise You.

Netflix Falls Below $60. Bill Ackman Explains Why That's an Incredible Investment Opportunity.

Billionaire David Tepper Just Made a Massive AI Chip Rotation --- Will It Pay Off?

The Cost of Losing Jensen Huang Goes Far Beyond $2.5 Trillion

If a Stock Market Crash Is Coming, Warren Buffett Says This Is the No. 1 Move All Investors Should Make
![[Analysis] Reasons Why This Bitcoin Decline Is Different from the Past](/public-static/30_f8d737795f.png?format=avif)
[Analysis] Reasons Why This Bitcoin Decline Is Different from the Past

2 Financial Stocks to Buy Near Their 52-Week Lows

US Treasury sells $15 billion in first nine-day cash bill auction since 2008

Not Anthropic. Not SpaceX. This Is the AI Stock to Buy for the Long Term

Bitcoin Has Traded Below Its 200-Week Average Only 8.4% of the Time. History Says This Is When Patient Investors Get Paid.

Greg Abel Just Approved a Record $9.6 Billion in Stock Buybacks for Berkshire Hathaway Last Quarter, More Than Double the Pace Set in the Second Quarter. Is Berkshire Still a Buy as Shares Sit Near All-Time Highs?

Solana Heads Towards Its Worst Year in History

If AI Chips Become Commoditized, Nvidia Has the Most to Lose, While These 3 Stocks Are Set to Gain

3 Data Center Power Stocks Down More Than a Third From Their Records to Buy Now and Hold Through 2030

NFT sales rise to $33M as Ethereum trading jumps 33%









